NPJ breast cancer · 2025
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Potter Shelley, Avery Kerry, Ahmed Rosina, de Boniface Jana, Chatterjee Sanjoy, Dodwell David, Dubsky Peter, Federmann Jingjing, Finestone Sandra, Gnant Michael, Hlauschek Dominik, Iwata Hiroji, Jiang Michael Y, Kaidar-Person Orit, Lee Han-Byoel, MacKenzie Mairead, Meyn Anne, Poortmans Philip, Poulakaki Fiorita, Richardson Andrea L, Sepulveda Karla A, Spillane Andrew J, Thompson Alastair M, Werutsky Gustavo, Wittmann Philipp, Wright Jean L, Zdenkowski Nicholas, Cowan Katherine, McIntosh Stuart A, PRECEDENT Study Group
Аннотация
Accurate information about locoregional breast cancer treatments following neoadjuvant systemic therapy (NST) is essential for meaningful interpretation of oncological outcomes but reporting is currently poor. We developed a core outcome set (COS) to improve the quality and consistency of locoregional outcome reporting in breast cancer NST trials. The COS was developed in three phases according to COS-STAD guidance, with the generation of a list of relevant outcome domains, prioritisation of outcomes through two rounds of an international online multi-stakeholder Delphi survey and a consensus meeting. 159 unique locoregional outcomes were classified into 101 outcome domains for inclusion in the Delphi survey, which was completed by 470 international professionals. The final 15-item COS, which included the pre-NST surgical plan, details of surgery performed following completion of treatment and details of radiation therapy, was agreed at an in-person consensus meeting. Widespread COS implementation will improve the quality and value of future NST trials.